Equities Analysts Offer Predictions for RARE Q2 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities research analysts at Wedbush cut their Q2 2025 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a report released on Monday, July 14th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of ($1.12) for the quarter, down from their prior estimate of ($1.08). Wedbush has a "Neutral" rating and a $34.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical's Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($4.66) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($3.07) EPS, FY2027 earnings at ($1.46) EPS, FY2028 earnings at $0.31 EPS and FY2029 earnings at $1.87 EPS.

Other equities analysts have also issued research reports about the company. Wells Fargo & Company dropped their price objective on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. Morgan Stanley reduced their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday. Guggenheim restated a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. William Blair began coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price for the company. Finally, JPMorgan Chase & Co. boosted their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $83.64.

Ultragenyx Pharmaceutical Stock Up 2.1%

RARE stock traded up $0.57 during trading on Wednesday, reaching $27.88. The company's stock had a trading volume of 1,275,905 shares, compared to its average volume of 958,549. The company's fifty day moving average is $36.00 and its 200-day moving average is $38.46. The company has a market capitalization of $2.64 billion, a P/E ratio of -4.73 and a beta of 0.26. Ultragenyx Pharmaceutical has a 1 year low of $26.85 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The firm had revenue of $139.29 million during the quarter, compared to analysts' expectations of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. The business's revenue for the quarter was up 28.0% on a year-over-year basis. During the same period last year, the company earned ($2.03) earnings per share.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the company. Parallel Advisors LLC lifted its stake in Ultragenyx Pharmaceutical by 1,061.9% in the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 669 shares during the last quarter. GAMMA Investing LLC increased its stake in Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $35,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Ultragenyx Pharmaceutical during the first quarter valued at $57,000. Finally, Headlands Technologies LLC bought a new stake in Ultragenyx Pharmaceutical during the 1st quarter valued at about $59,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the sale, the director owned 15,344 shares in the company, valued at approximately $573,712.16. This represents a 13.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 3,167 shares of company stock valued at $118,824. 5.50% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.